Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

2.

Modulation of central cholinergic activity by GABA and serotonin: PET studies with 11C-benztropine in primates.

Dewey SL, Smith GS, Logan J, Brodie JD.

Neuropsychopharmacology. 1993 Jun;8(4):371-6.

3.

6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine.

Roberts AC, De Salvia MA, Wilkinson LS, Collins P, Muir JL, Everitt BJ, Robbins TW.

J Neurosci. 1994 May;14(5 Pt 1):2531-44.

4.

D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study.

Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kerwin RW.

Br J Psychiatry. 1994 Jan;164(1):16-26.

PMID:
8137105
6.

Imaging endogenous dopamine competition with [11C]raclopride in the human brain.

Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R, Lieberman J, Angrist B, Pappas N, MacGregor R, et al.

Synapse. 1994 Apr;16(4):255-62.

PMID:
8059335
7.

Elevated dopa decarboxylase activity in living brain of patients with psychosis.

Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A.

Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11651-4.

8.
9.

Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone.

Tune LE, Wong DF, Pearlson G, Strauss M, Young T, Shaya EK, Dannals RF, Wilson AA, Ravert HT, Sapp J, et al.

Psychiatry Res. 1993 Dec;49(3):219-37.

PMID:
7909948
10.

Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.

Hietala J, Syvälahti E, Vuorio K, Någren K, Lehikoinen P, Ruotsalainen U, Räkköläinen V, Lehtinen V, Wegelius U.

Arch Gen Psychiatry. 1994 Feb;51(2):116-23.

PMID:
7905257
11.

SPECT imaging of striatal dopamine release after amphetamine challenge.

Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, et al.

J Nucl Med. 1995 Jul;36(7):1182-90.

12.

Reevaluation of the mesolimbic hypothesis of antipsychotic drug action.

Lidsky TI.

Schizophr Bull. 1995;21(1):67-74. Review.

PMID:
7770742
13.

Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport.

Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A.

J Neurosci. 1995 May;15(5 Pt 2):4102-8.

14.
15.
16.
17.
18.

Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder.

Cross AJ, Crow TJ, Ferrier IN, Johnstone EC, McCreadie RM, Owen F, Owens DG, Poulter M.

J Neural Transm Suppl. 1983;18:265-72. No abstract available.

PMID:
6135745
19.

The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs.

van Rossum JM.

Arch Int Pharmacodyn Ther. 1966 Apr;160(2):492-4. No abstract available.

PMID:
5954044
20.

Supplemental Content

Support Center